GSK’s older adult … vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6%

GSK’s older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial

• Data to be presented at IDWeek 2022 showed overall vaccine efficacy against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with a favourable safety profile

• Consistent high vaccine efficacy observed against LRTD in severe disease (94.1%), adults aged 70-79 years (93.8%) and in adults with underlying comorbidities (94.6%)

• High vaccine efficacy is consistent across RSV A and B strains

GSK plc (LSE/NYSE: GSK) today announced positive pivotal phase III trial results for its respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above to be presented at IDWeek 2022. The vaccine candidate was highly efficacious, demonstrating overall vaccine efficacy of 82.6% (96.95% CI, 57.9–94.1, 7 of 12,466 vs. 40 of 12,494) against RSV lower respiratory tract disease (RSV-LRTD), meeting the trial’s primary endpoint.

https://www.gsk.com/en-gb/media/pre...ratory-syncytial-virus-rsv-vaccine-candidate/